date,title,source
Oct-30-18,BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation,GlobeNewswire
Oct-31-18,BioXcel Therapeutics Announces Presentation on Functional Immunological Memory Formation Across Diverse Tumor Types at the SITC 2018 Annual Meeting,GlobeNewswire
Nov-05-18,"BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer",GlobeNewswire
Nov-09-18,BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update,GlobeNewswire
